RETA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
RETA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Reata Pharmaceuticals's Enterprise Value is $6,402.23 Mil. Reata Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was $-47.07 Mil. Therefore, Reata Pharmaceuticals's EV-to-EBIT for today is -136.03.
The historical rank and industry rank for Reata Pharmaceuticals's EV-to-EBIT or its related term are showing as below:
During the past 10 years, the highest EV-to-EBIT of Reata Pharmaceuticals was -1.36. The lowest was -295.12. And the median was -17.75.
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Reata Pharmaceuticals's Enterprise Value for the quarter that ended in Jun. 2023 was $3,694.65 Mil. Reata Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was $-47.07 Mil. Reata Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was -1.27%.
The historical data trend for Reata Pharmaceuticals's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Reata Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||||
EV-to-EBIT | Get a 7-Day Free Trial | -18.96 | -22.50 | -15.66 | -2.07 | -4.17 |
Reata Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | |
EV-to-EBIT | Get a 7-Day Free Trial | -3.00 | -2.34 | -4.17 | -10.31 | -78.50 |
For the Biotechnology subindustry, Reata Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Reata Pharmaceuticals's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Reata Pharmaceuticals's EV-to-EBIT falls into.
Reata Pharmaceuticals's EV-to-EBIT for today is calculated as:
EV-to-EBIT | = | Enterprise Value (Today) | / | EBIT (TTM) |
= | 6402.233 | / | -47.065 | |
= | -136.03 |
Reata Pharmaceuticals's current Enterprise Value is $6,402.23 Mil.
Reata Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-47.07 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Reata Pharmaceuticals (NAS:RETA) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.
Reata Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 is calculated as:
Earnings Yield (Joel Greenblatt) % (Q: Jun. 2023 ) | = | EBIT | / | Enterprise Value (Q: Jun. 2023 ) |
= | -47.065 | / | 3694.648728 | |
= | -1.27 % |
Reata Pharmaceuticals's Enterprise Value for the quarter that ended in Jun. 2023 was $3,694.65 Mil.
Reata Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-47.07 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Reata Pharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Steven Ryder | director | 234 CHURCH STREET, SUITE 1020, NEW HAVEN CT 06510 |
Antal Rohit Desai | director, 10 percent owner | C/O PROCEPT BIOROBOTICS CORPORATION, 900 ISLAND DRIVE, REDWOOD CITY CA 94065 |
Rajiv Patni | officer: EVP, Chief R&D Officer | C/O OCERA THERAPEUTICS, INC., 525 UNIVERSITY AVENUE, SUITE 610, PALO ALTO CA 94301 |
Bhaskar Anand | officer: SVP, Chief Accounting Officer | 5320 LEGACY DRIVE, PLANO TX 75024 |
Manmeet Singh Soni | officer: COO, CFO and President | C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE, SUNNYVALE CA 94085 |
Martin Edwards | director | 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803 |
Dawn Carter Bir | officer: Chief Commercial Officer | C/O REATA PHARMACEUTICALS, INC., 2801 GATEWAY DRIVE, SUITE 150, IRVING TX 75063 |
Christy J. Oliger | director | 85 WELLS AVENUE, SUITE 210, NEWTON MA 02459 |
Andrea Loewen | officer: SVP, Global Regulatory Affairs | C/O VITAL THERAPIES, INC., 15010 AVENUE OF SCIENCE, SUITE 200, SAN DIEGO CA 92128 |
Shamim Ruff | director | 215 FIRST STREET, SUITE 415, CAMBRIDGE MA 02142 |
Mcclellan William D. Jr. | director | C/O APOLLO ENDOSURGERY, INC., 1120 S., CAPITAL OF TEXAS HWY, BLDG. 1, SUITE 300, AUSTIN TX 78746 |
Michael D Wortley | officer: See Remarks | 5320 LEGACY DRIVE, PLANO TX 75024 |
Meyer Colin John | officer: See Remarks | C/O REATA PHARMACEUTICALS, INC., 2801 GATEWAY DR. SUITE 150, IRVING TX 75063 |
Biogen Inc. | other: See footnotes | 225 BINNEY STREET, CAMBRIDGE MA 02142 |
Samina Khan | officer: SVP, Chief Medical Officer | 5320 LEGACY DRIVE, PLANO TX 75024 |
From GuruFocus
By Business Wire • 08-03-2023
By Marketwired • 07-28-2023
By GuruFocus Research • 06-15-2023
By PRNewswire PRNewswire • 05-29-2023
By PRNewswire PRNewswire • 06-09-2023
By PRNewswire PRNewswire • 05-30-2023
By GuruFocus Research • 09-08-2023
By Marketwired • 08-03-2023
By PRNewswire PRNewswire • 06-07-2023
By PRNewswire PRNewswire • 06-02-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.